Literature DB >> 16671903

Variable phenotypes in patients diagnosed with idiopathic multifocal choroiditis.

Robert E MacLaren1, Susan L Lightman.   

Abstract

PURPOSE: To report investigations in a case series of patients diagnosed with idiopathic multifocal choroiditis (MFC) in order to determine whether or not a new clinical phenotype could be identified and to determine the long-term visual prognosis.
METHODS: Twenty-eight patients were identified from the clinic database of approximately 1200 and subsequently reviewed. After ocular examination, which included fluorescein angiography, 20 of these patients were determined to have idiopathic MFC. Visual outcome, patient demographics, presenting symptoms, the distribution of inflammatory cells, the pattern of chorioretinal lesions and the development of peripapillary atrophy, choroidal new vessels or cystoid macular oedema were compared.
RESULTS: The range of follow up was 1-27 years (mean 10 years). A Kaplan-Meier plot showed that approximately 60% of patients maintained their best-corrected visual acuity for 10 years after diagnosis. Poor vision at final review was associated with eyes having choroidal new vessels or cystoid macular oedema. Oral steroids were used to treat 11 patients, of which 10 responded with a visual improvement. The one non-responsive patient had foveal ischaemia angiographically. Generally the idiopathic phenotype was variable and only four patients showed some overlap with known subgroups of MFC. Unusual vascular features were observed in two patients.
CONCLUSIONS: No specific phenotype was seen to emerge from this cohort of patients diagnosed with idiopathic MFC, although most were significantly different from the retinal white dot syndromes currently described. The visual prognosis was relatively good and most cases responded to oral steroids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671903     DOI: 10.1111/j.1442-9071.2006.01191.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  3 in total

1.  Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome.

Authors:  Doukas Dardabounis; Efstratios Alvanos; Zisis Gatzioufas; Georgios D Panos
Journal:  BMJ Case Rep       Date:  2013-07-17

2.  Two Novel CAPN5 Variants Associated with Mild and Severe Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Phenotypes.

Authors:  Nadia M Randazzo; Morag E Shanks; Penny Clouston; Robert E MacLaren
Journal:  Ocul Immunol Inflamm       Date:  2017-10-17       Impact factor: 3.070

Review 3.  Gender differences in birdshot chorioretinopathy and the white dot syndromes: do they exist?

Authors:  Lisa J Faia
Journal:  J Ophthalmol       Date:  2014-02-09       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.